CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary
Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is driven by SMARCA4 loss. Here the authors demonstrate that SCCOHT cells are highly sensitive to CDK4/6 inhibition and provide mechanistic insights, whereby this druggable vulnerability is driven by cyclin D1 deficiency induced by SMARC...
Guardado en:
Autores principales: | Yibo Xue, Brian Meehan, Elizabeth Macdonald, Sriram Venneti, Xue Qing D. Wang, Leora Witkowski, Petar Jelinic, Tim Kong, Daniel Martinez, Geneviève Morin, Michelle Firlit, Atefeh Abedini, Radia M. Johnson, Regina Cencic, Jay Patibandla, Hongbo Chen, Andreas I. Papadakis, Aurelie Auguste, Iris de Rink, Ron M. Kerkhoven, Nicholas Bertos, Walter H. Gotlieb, Blaise A. Clarke, Alexandra Leary, Michael Witcher, Marie-Christine Guiot, Jerry Pelletier, Josée Dostie, Morag Park, Alexander R. Judkins, Ralf Hass, Douglas A. Levine, Janusz Rak, Barbara Vanderhyden, William D. Foulkes, Sidong Huang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a9bfc57c02f44dfc91dacd68ff8a6a66 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
por: Yibo Xue, et al.
Publicado: (2019) -
SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca2+ flux to mitochondria
por: Yibo Xue, et al.
Publicado: (2021) -
Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer
por: Katharina Leitner, et al.
Publicado: (2020) -
BET inhibitor suppresses migration of human hepatocellular carcinoma by inhibiting SMARCA4
por: Hae In Choi, et al.
Publicado: (2021) -
SOX4 and SMARCA4 cooperatively regulate PI3k signaling through transcriptional activation of TGFBR2
por: Gaurav A. Mehta, et al.
Publicado: (2021)